Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tafamidis (Vyndaqel): a light for FAP patients.

ChemMedChem - 1 Oct 2013

Nencetti Susanna, Rossello Armando, Orlandini Elisabetta

Abstract excerpt

Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer. Tafamidis acts in a similar way to the natural hormone T4, prevents TTR amyloid fibril formation, and offers a potential alternative to liver transplantation for the treatment of patients with TTR familial amyloid polyneuropathies (TTR-FAP).

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Binding Sites
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TTR gene

Share to Mutation

Share to Prealbumin

Share to Protein Binding

Share to Protein Structure, Tertiary

Source

Identifiers

PMID: 24000164
DOI: 10.1002/cmdc.201300245

Genes

TTR
FAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tafamidis (Vyndaqel): a light for FAP patients.PMID 24000164Read ↗

Tafamidis for transthyretin amyloidosis.Semantic proximity Read ↗

TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathiesSemantic proximity Read ↗

FAP neuropathy and emerging treatments.Semantic proximity Read ↗

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.Semantic proximity Read ↗

Current and future treatment of amyloid neuropathies.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

[Treatment of familial amyloid polyneuropathy].Semantic proximity Read ↗

[Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].Semantic proximity Read ↗

[Hereditary transthyretin amyloidosis].Semantic proximity Read ↗

Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.Semantic proximity Read ↗

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.